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New blood vessel formation within tumours is a critical feature for tumour growth. A major limitation in understanding this complex
process has been the inability to visualise and analyse vessel formation. Here, we report on the development of a whole-tissue mount
technique that allows visualisation of vessel structure. Mice expressing green fluorescent protein (GFP) made it possible to easily see
GFP
þ vessels within non-GFP-expressing B16 melanoma tumours. The small fragments of tumour used in this technique were also
effectively stained with fluorescent probe-conjugated antibodies, allowing characterisation of the vessels based on surface marker
phenotype. The vessels within tumour tissue were much more irregular and tortuous compared to those within surrounding normal
muscle. B16 tumours stably transfected with the genes for IL-12 were used to assess the effects of this cytokine on tumour growth
and vessel formation. The IL-12-expressing tumours grew more slowly and had much smaller blood vessels than the large, webbed
vessels characteristic of the parental tumours, effects that were dependent on interferon gamma (IFN-g). Vessels in the parental
tumours were found to express VEGFR-3, the receptor for VEGF-C and VEGF-D. Expression of this receptor by the endothelial cells
of the blood vessels was lost in the cytokine expressing tumours, thus suggesting a mechanism for the antiangiogenic effects of IL-12.
The combination of the whole mount technique and the GFP transgenic mice provides a powerful method for visualising tumour
vasculature and characterising the effects of agents such as cytokines.
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Angiogenesis is a multistep process that is limited and carefully
regulated in normal adult tissue, but in tumours this regulation is
disrupted and the process remains ‘switched on’ (Hanahan and
Folkman, 1996). Ample experimental data support the fact that
tumour growth requires access to blood vessels and subsequent
expansion of host vessels to provide nutrients for the growing
tumour mass (Folkman, 1995a). Furthermore, many studies in a
variety of tumour types have reported a correlation between the
extent of tumour vasculature and poor prognosis or increased
metastases (Weidner et al, 1991; Folkman, 1995b; Weidner and
Folkman, 1996). Thus, accurate assessment of the vasculature of
tumours could provide valuable information regarding treatment
outcomes and the likelihood of metastatic spread to other sites.
Angiogenesis can be regulated by a variety of factors. Several
cytokines produced by immune cells also have been shown to
affect the process of angiogenesis. One of the most noteworthy is
interleukin (IL)-12, which is produced by antigen presenting cells
(APC), such as macrophages and dendritic cells (DC) in response
to bacterial stimuli or other inflammatory cytokines. Thus, IL-12
plays an important role in both the innate and adaptive immune
responses (Trinchieri, 1998). Owing to its central role in
stimulating immunity, it has been examined for possible
therapeutic effects in the treatment of tumours. In addition to its
effects on the immune system, IL-12 has also been shown to inhibit
angiogenesis (Voest et al, 1995; Sgadari et al, 1996). Despite studies
in both experimental models and in patients (reviewed in
Trinchieri and Scott, 1999), and clear demonstrations of ther-
apeutic efficacy, relatively little is known about how it alters vessel
formation within tumours. In part, this is due to the difficulty in
assessing the three-dimensional structure of vessels and other
cellular components within the tumour. Assessment of tumour
vessels is generally based on immunohistochemistry of tumour
sections. Although use of this technique has led to a great deal of
important information, these procedures are extremely time
consuming and provide only a limited two-dimensional view of
the vessels. This makes it very difficult to visualise the structure of
the microvasculature and identify differences among different
tumour types or changes following treatment regimens. To more
easily and accurately visualise vessels within tumours, we
developed a whole-tissue mount technique that provides a three-
dimensional view of the tumour vasculature relative to other
components of the tumour tissue. This technique was first
validated by studying vessels from transgenic mice that express
green fluorescent protein (GFP) (Wu et al, 2000), and then used to
investigate the mechanism by which IL-12 influences the vessel
architecture within B16 tumours.
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sMATERIALS AND METHODS
Mice
C57BL/6J and B6.129S7-Ifng
tm1Ts (IFN-g deficient) mice were
purchased from the Jackson Laboratory (Bar Harbor, ME, USA).
Green fluorescent protein-transgenic mice (C57BL/6-H-2K
bP-GFP)
were generated as previously described (Wu et al, 2000). The
transgenic mice were bred in our animal facility at the University
of Rochester, and typed prior to usage by flow cytometric analysis
of peripheral lymphocytes. Guidelines for the humane treatment of
animals were followed as approved by the University Committee
on Animal Resources and meet the standards required by the
UKCCCR guidelines (Workman et al, 1998).
Construction of expression vector for IL-12
The expression vector pmIL-12-neo.1 was made by excising a
4405-bp fragment from pWRG 3169 (a kind gift from Dr Hua Yu
(Rakhmilevich et al, 1996; Tan et al, 1996)), which contained the
p35 and p40 subunit genes for mIL-12, each under control of a
CMV promotor, using KpnI and SpeI. This was inserted into a
modified pEGFP-1 expression vector (Clontech, Palo Alto, CA,
USA) in which KpnI/XbaI sites were created by removing the EGFP
gene. The final construct contained both IL-12 genes and a neo-
selectable marker.
Cell lines
The B16-F0 cell line, a C57BL/6 (H-2
b) spontaneously arising
melanoma, was obtained from the ATCC (CRL 6322) and
maintained in MAT/P medium (USA patent #4.816.401) supple-
mented with 100Uml
 1 penicillin, 100mgml
 1 streptomycin and
2% fetal calf serum. The B16 IL-12-expressing line (B16/IL-12) was
constructed using the pmIL-12-neo.1 plasmid as described above.
B16-F0 cells were transfected using Lipofectin (BRL, Gaithersburg,
MD, USA), according to the manufacturer’s directions. At 24h
after transfection, selection of transfectants was initiated with
400mgml
 1 G418 (Gibco, Grand Island, NY, USA); 10–14 days
later, cells were cloned at limiting dilution. Clones were expanded
and tested for IL-12 (p70) production by ELISA. This assay was
specific for IL-12 p70 by virtue of the use of a rat anti-mouse IL-12
(p70) capture antibody (BD Pharmingen, clone 9A5), which reacts
with the p70 heterodimer but does not react with the p40 subunit.
Bound IL-12 (p70) was then detected with a biotin-conjugated
anti-mouse IL-12 (p70/p40) antibody (BD Pharmingen, clone
C17.8). All washes were carried out in the absence of azide, and a
recombinant IL-12 (p70) standard (BD Pharmingen) at
4000pgml
 1 was run in each assay.
Tumour growth in vivo
Tumour cells in 100ml of Hanks balanced salt solution (HBSS)
(Sigma, St Louis, MO, USA) were injected intramuscularly into the
thighs of C57BL/6 or C57BL/6-H-2K
bP-GFP mice. Mean thigh
diameter was determined as described previously (McAdam et al,
1995). Since the B16 and B16/IL-12 tumours grew at different rates,
the tumours were allowed to grow for different times and used in
experiments when the thigh diameter had reached 10–13mm.
Immunohistochemistry and image analysis
Whole mount histology was performed by excising small pieces
(B2mm 3mm 1mm) from the tumour and placing it on a
glass slide with two drops of PBA (phosphate-buffered salineþ1%
bovine serum albuminþ0.1% sodium azide) (Sigma, St Louis,
MO, USA). A coverslip was placed on top of the piece of tumour,
gently pressed down and excess PBA removed by blotting with
absorbent tissue. This tumour fragment was then viewed via
fluorescence microscopy. Analysis of these fragments by confocal
microscopy showed them to be of fairly uniform thickness
(B100mm). To ensure uniform thickness we subsequently
constructed a frame mounted to a glass slide, which placed
uniform pressure on the entire perimeter of the coverslip (using
screws machined to stop at 100mm) so that each fragment would
be 100mm in depth. Owing to the heterogeneity inherent both
within and between tumours, several pieces (six to nine) from
different areas were examined from each tumour and several
tumours (three to six) were used in each study.
Samples to be stained with antibodies were placed in 6ml
polypropylene tubes, and the samples blocked using Fc Block
(PharMingen, San Diego, CA, USA) at 10mgml
 1 in 200ml of PBA
with shaking at 41C for 20min. Primary antibody was added
directly to the tube at the predetermined concentration and
incubated with shaking at 41C for 1–1.5h. The sample was washed
twice by adding 4ml of PBA to each tube and rotating at 41C for
1h. For samples requiring a second step reagent, the PBA was
aspirated and streptavidin-fluorochrome (PharMingen, San Diego,
CA, USA) was added at 1:400 in 200ml PBA and incubated with
shaking at 41C for 1–1.5h, followed by washing as described
above. After the final wash, samples were removed from the tubes
using 1000ml pipette tips with tip cutoff, and placed on slides as
described above. To control for possible nonspecific binding of the
antibodies, additional samples were stained with either a directly
conjugated antibody of the same isotype as the primary antibody,
or unconjugated antibody of the same isotype followed by
streptavidin–biotin or streptavidin–biotin alone. In all cases,
background staining was extremely low or nonexistent.
Conventional immunohistochemistry was performed using 4mm
cryostat sections mounted on poly-L-lysine coated slides and
stored at  801C. Staining was performed on unfixed sections,
blocked with Fc block and stained as for the whole mount
technique except that 100ml of antibodies, diluted in PBA to the
predetermined concentration were placed on the sections and the
slides incubated in a humid box.
Vessel quantification
The percent vessel area was determined on antibody-stained whole
mounts prepared as described above. Each tumour was stained
with phycoerythrin (PE)-conjugated anti-CD31 or anti-panen-
dothelial cell (PanEC) (PharMingen, San Diego, CA, USA), and
30–35 digital images ( 10 objective) were obtained per tumour.
Images were analysed using Image Pro Software by colour
segmenting each image using a predefined colour range to form
a binary image of the tumour blood vessels. From these images,
percent vessel area was then computed for each image and
averaged to obtain percent vascular area. Tumour vessel diameters
were determined on whole mounts stained in the same manner.
For these determinations 25–30 digital images ( 10 objective)
were obtained per tumour. In each image, vessels were manually
selected and diameters of all vessels were determined, using Image
Pro Manual Measurement techniques, and exported to Microsoft
Excel for statistical analysis. More than 500 (524–1323) vessels
were measured for each tumour.
RESULTS
Examination of blood vessels in normal tissues
of GFP mice
Expression of the GFP gene in the transgenic mice used for this
study is under the control of the MHC class I promotor (Wu et al,
2000), and thus like class I, would be expected to be expressed in
essentially all somatic tissues (Daar et al, 1984). To visualise GFP
expression, we developed a whole-tissue mount technique, in
IL-12 alterations in tumour blood vessels
SA Gerber et al
1454
British Journal of Cancer (2003) 88(9), 1453–1461 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
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manipulation (see Materials and Methods). This greatly increased
the visibility of the GFP, presumably because the viable cells
retained GFP expression, and also maintained much of the spatial
relations within the tissue. Using this technique, we observed high
levels of GFP expression in tissues such as kidney and liver (data
not shown), whereas brain tissue generally expressed very low
levels. These GFP expression levels correlate well with reported
expression levels of class I (Daar et al, 1984). The brain offers a
good example of a tissue that is low in both class I and GFP
expression, but interestingly, it also contained structures that were
strongly fluorescent, which had the morphology of blood vessels
(Figure 1A,C). To confirm the identity of these structures, we
determined their expression of the adhesion molecule, PECAM-1
(platelet endothelial cell adhesion molecule) or CD31, known to be
strongly expressed on endothelial cells lining blood vessels
(Figure 1B). We speculated that sufficient antibodies might be
able to penetrate the small tumour pieces. The tumour fragments
were incubated with PE-conjugated anti-CD31, and the antibody
was found to penetrate readily the brain tissue and stain the GFP
þ
structures, thus confirming that they were indeed blood vessels.
Fragments of the brain tissue were incubated with a PE-conjugated
anti-class I antibody, which also stained the blood vessels quite
brightly, whereas the surrounding brain tissue was largely
unstained (Figure 1D). Fragments stained with a PE-isotype
control showed minimal staining (data not shown). Thus, the
increased class I expression on the vessels provided an explanation
for the observed greater expression of GFP. These results with
normal brain tissue indicated that blood vessels should be visible
within implanted GFP-negative tumour tissue, and confirmed that
fluorochrome-conjugated antibodies could penetrate the tissues.
Blood vessels in B16 tumours (GFP and CD31 staining)
To assess vessel formation within growing tumours, B16 melano-
ma cells were injected intramuscularly into the hindlimbs of GFP
transgenic mice and allowed to grow until the leg diameter was
10–13mm at which time the tumours were removed. Since B16
tumours grow as soft masses of tissue, it was very easy to prepare
the whole mounts, which allowed visualisation of the tumour
vessels with apparently minimal disturbance of the spatial
relations. Although the tissue viewed by bright field was
unremarkable (Figure 2A), the same tissue viewed for green
fluorescence revealed a rich network of blood vessels visible as
complete three-dimensional structures (Figure 2B). The vascular
identity of these structures was verified by staining with PE-anti-
CD31 (Figure 2C). As with the brain tissue, the antibodies were
found to penetrate throughout the small fragments of tumour
tissue, and samples stained with a PE-isotype control showed
negligible staining (data not shown).
Growth kinetics of parental and cytokine-expressing
tumours
Previous studies have shown that local production of cytokines
within tumours can have a marked effect on vascularisation. In
particular, IL-12 has been shown to inhibit angiogenesis (Voest
et al, 1995). However, little information is available on the three-
dimensional structure of the vessels or the mechanism of action of
IL-12. In the current study, we have used the whole mount
technique to examine IL-12-expressing tumours and to address
these issues. B16 tumours were transfected with the gene for IL-12
as previously described and stable transfectants selected. The
stably transfected clone used in these studies produced an average
of 10ng IL-12 per 10
6 cells and proliferated at the same rate in vitro
as the untransfected cells (Figure 3A). Preliminary experiments
revealed that the IL-12-expressing tumours implanted in C57BL/6
mice grew much slower than the parental or mock transfected
tumours (data not shown). To match the parental B16 tumour
growth rates more closely, the number of transfected cells injected
was increased five-fold to 1 10
6 cells. Mice injected with
this number of cells had tumour bearing leg diameters of
AB
C D
Figure 1 GFP expression in normal brain tissue of C57BL/6-H-2K
bP-GFP (GFP transgenic) mice. Whole-tissue mounts of brain tissue from GFP transgenic
mice were viewed using an FITC filter set (A, C) or alternatively stained with PE-anti-CD31 (B) or with PE-anti-H-2K
b (D) and viewed using a PE filter set.
All images are at the same magnification with the white bar representing 100mm.
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shows representative growth curves for these tumours. Even with
injection of an increased number of cells, the IL-12-expressing
tumours grew more slowly than the parental tumours.
Analysis of vessel morphology in parental and
IL-12-expressing tumours
Whole mount preparations for these tumours revealed striking
differences in the vasculature between the parental and IL-12-
expressing B16 tumours that may explain the altered tumour
growth observed. Images composed of montages of 16 microscope
fields ( 10 objective) encompassing an area of approximately
3.2 4.2mm were prepared from pieces of size matched B16 and
B16/IL-12 tumours (Figure 4A,C). Vessels in the parental tumours
appear larger and are much easier to discern than are the vessels in
the IL-12-expressing tumours. Paraffin sections of each type of
tumour were also prepared and stained with haematoxylin and
eosin to visualise the morphology of these tumours by conven-
tional histology (Figure 4B,D). The sections from both the parental
and IL-12-expressing tumours show regions of viable tissue taken
from progressively growing tumours. The parental tumour tissue
appears to have more vessels as well as ‘blood lakes’, regions of
pooled blood resulting from leaky and haemorrhagic vessels often
observed within tumours (Yancopoulos et al, 2000).
To distinguish more easily the morphology differences and to
visualise the vessels exclusively, the tumour fragments were
stained with biotin-conjugated MECA-32, an antibody to the
panEC antigen and detected with PE–streptavidin (Figure 5). This
antigen is expressed on endothelial cells, but not leucocytes
(Leppink et al, 1989; Hallmann et al, 1995), thus making it possible
to observe the vessels easily without visualising the GFP
þ
infiltrated host cells. The large, webbed or honeycombed vessels
observed in the parental B16 tumours are characteristic of
immature angiogenic vessels that have not yet undergone extensive
remodelling. The whole mount technique provides an excellent
three-dimensional view of these newly formed vessels. In contrast,
the vessels in the IL-12-expressing tumours had a much different
morphology. They appeared to be much smaller in diameter, and
also longer and less convoluted than the vessels in the parental
tumours.
A
B
C
Figure 2 GFP
þ blood vessels in parental B16 tumours. A whole-tissue
mount preparation of a parental B16 tumour grown in a GFP
þ mouse,
stained with PE-anti-CD31 and viewed by (A) bright-field or (B)
fluorescence using a GFP filter set or a (C) PE-filter set. The images are
all of the same field with the bar representing 100mm.
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Figure 3 Growth of B16 parental and cytokine-transfected tumour cells
in vitro and in vivo in GFP mice. (A)1  10
5 parental (circles) or IL-12-
transfected (squares) B16 tumour cells were plated in vitro. At daily
intervals, cells were removed from triplicate plates and counted individually.
Points are the mean and standard deviation of the counts. (B)2  10
5
parental (circles), or 1 10
6 B16/IL-12 (squares) tumour cells were
implanted intramuscularly in the leg of syngeneic C57BL/6-H-2K
bP-GFP
mice and tumour growth followed by measuring the leg diameter. Each line
represents tumour growth in an individual mouse.
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To better understand the mechanism by which IL-12 exerts its
growth inhibitory and vascular effects in the B16-tumour system,
we examined the role of downstream cytokines, particularly IFN-g.
To assess the role of IFN-g in the vessel changes observed in the
B16/IL-12 tumours, we also implanted the IL-12-expressing
tumour cells into IFN-g-deficient mice. As can be seen from the
image in Figure 5C, the vessels in the B16/IL-12 tumours growing
in these mice are intermediate in size and morphology compared
to those in the parental and the IL-12 tumours growing in wild-
type mice. The tumours also grew faster in these mice compared to
the same cells in C57BL/6 mice, with kinetics similar to parental
cells (data not shown). This intermediate vascular phenotype and
reversal of the tumour growth inhibition indicate that IFN-g is
involved in the IL-12-mediated effects in this system, although it
does not account for all of the effects.
The alterations in vasculature between the parental and the
IL-12-expressing tumours were quantified by measuring two
parameters. The first parameter involved determining the percen-
tage of the field that was occupied by vessels, which provides the
relative amount of vascular area within each tumour type. Using
this measure, the IL-12-expressing tumours had significantly less
vascular area than did the parental tumours (Figure 6A), whereas
the vascular area of the IL-12-expressing tumours grown in the
IFN-g-deficient mice was intermediate. The second parameter
measured was the diameter of the vessels present in each tumour
type, which was determined by measuring all vessels in several
fields. For these measurements, an individual vessel was defined as
the unbranched segment between junctions. Mean vessel diameters
in the IL-12-expressing tumours were significantly smaller than
in the parental tumours when both were grown in wild-type
mice. As suggested by the images of Figure 5, the vessels in the
IL-12-expressing tumours grown in the IFN-g-deficient animals
were intermediate in diameter. By this measure, the vessels in the
IL-12-expressing tumours grown in the IFN-g-deficient animals
were also significantly different from the parental cells, but not
different from the IL-12-expressing tumours grown in wild-type
mice. In all three cases, the tumour vessels had a significantly
larger diameter than vessels from normal muscle. The data are also
shown as a frequency histogram (Figure 6C), which clearly shows
that the differences are primarily in vessels with diameters from
10 to 30mm.
Altered expression of vascular endothelial growth
factor (VEGF) receptor 3 on blood vessels in
IL-12-expressing tumours
To better understand the mechanism of action of the IL-12-
mediated changes in vessel structure and morphology, we analysed
one of the most potent angiogenic factors expressed by tumour
cells, vascular endothelial growth factor (VEGF) and its corre-
sponding receptors (VEGFR). Antibodies to VEGFR-1, VEGFR-2
and VEGFR-3 were used to stain vessels from the parental and IL-
12-expressing tumours. Both VEGFR-1 and VEGFR-2 were found
on vessels from both types of tumours and thus were unlikely to
account for the differences in vasculature between the two types of
tumour (data not shown). In contrast, VEGFR-3 expression, which
was clearly present on the vessels from the parental tumours, was
highly downregulated on the vessels from the IL-12-expressing
tumours. This can be clearly seen in the images in Figure 7A in
which the parental tumour GFP
þ blood vessels also stain with the
PE-anti-VEGFR-3 (top row of images). In the B16/IL-12 tumours,
GFP
þ blood vessels were also clearly visible, but these were
completely unstained with the anti-VEGFR-3 antibody (bottom
row of images), even though other cell types are seen to be VEGFR-
3 positive. To verify this finding, additional tumours were
examined by conventional immunohistochemistry (Figure 7B).
For these studies, blood vessels were identified by staining with
B16/IL-12
C D
B16
A B
Figure 4 Varying GFP fluorescence intensity of blood vessels in parental and cytokine-expressing tumours. Montages (16 microscopic fields) of whole-
tissue mounts of (A) B16 and (C) B16/IL-12 were prepared and imaged under identical conditions. Each montage illustrates a 3.2mm 4.2mm tissue piece.
The white bar represents 750mm. Paraffin sections from (B) B16 or (D) B16/IL-12 tumours were stained with haematoxylin and eosin. The black bars in (B)
and (D) represent 100mm.
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detected with streptavidin–APC. As with the whole mount
technique, immunohistochemistry of sections revealed VEGFR-3
expressed on vessels in the parental tumours but not on vessels
in the IL-12-expressing tumours. Thus, IL-12 appears to limit
the upregulation of VEGFR-3 on the vessels, thus preventing
stimulation of their growth by its known ligands, VEGF-C and
VEGF-D.
A
B
C
Figure 5 Visualisation of altered blood vessel morphology in cytokine-
expressing tumours. Whole-tumour mounts were prepared from (A) B16,
or (B) B16/IL-12 tumours grown in normal mice or (C) B16/IL-12 tumours
grown in IFN-g-deficient mice and stained with biotin-conjugated anti-
panEC and PE–streptavidin. All photographs are of the same magnification
with the white bar representing 200mm.
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Figure 6 Quantification of blood vessel diameter and area in parental
and cytokine-expressing tumours. (A) Percent vessel area was determined
for each of the three tumour types using whole mounts stained for either
CD31 or PanEC on 30–35 images ( 10 objective) per tumour and
analysed as detailed in Materials and Methods. Three B16, four B16/IL-12 in
C57BL/6 mice and two B16/IL-12 tumours in the IFN-g-deficient mice were
analysed. Significance as determined by the Bonferroni test, was Po0.001
for B16 compared to B16/IL-12 in wild-type mice and P¼0.012 for B16
compared to B16/IL-12 in IFN-g-deficient mice. There was no significant
difference between B16/IL-12 grown in wild-type and deficient mice. (B)
Average vessel diameter was determined using Image Pro software on
whole mounts stained for CD31, and based on 25–30 images ( 10
objective) for each tumour. Data shown are mean and standard error of
524–1323 vessel diameters per tumour type. For comparison, vessels from
normal leg muscle were also analysed. Significance was Po0.001 for B16
compared to B16/IL-12 in wild-type mice and P¼0.009 for B16 compared
to B16/IL-12 in IFN-g-deficient mice. There was no significant difference
between B16/IL-12 grown in wild-type and deficient mice. (C) Vessel
diameter distribution, based on 10mm intervals.
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sDISCUSSION
This study describes and validates a new whole mount method for
visualising and characterising the blood vessels within experi-
mental mouse tumours. The use of transgenic mice expressing
GFP under the control of the class I promotor greatly assisted
verification of the technique. In initial studies, we attempted to use
conventional immunocytochemistry to visualise blood vessels, but
encountered problems in detection of the GFP fluorescence (data
not shown), as has been previously described (Sullivan and Kay,
1999). Several factors probably contribute to this diminution of the
fluorescence. First, very thin sections generally are used (10mmo r
less) and since many of the vessels are cut as cross-sections, this
means that only two to three cells are being observed, resulting in
limited fluorescence intensity. Even with frozen sections, it is
typical to use some fixation method, which tends to affect the GFP
fluorescence intensity adversely. In contrast, the whole mount
method uses tissue fragments, making it possible to view large
segments (and hundreds of endothelial cells) of essentially intact
vessels. The tissue is neither fixed nor frozen, so GFP expression is
maintained at a high level within the viable cells. Compared to
conventional immunohistochemistry, this method is simpler,
faster and provides a more comprehensive view of the vascular
configuration within the tumour tissue.
Since the implanted tumours are GFP negative, they provide a
blank background on which the bright GFP fluorescent blood
vessels of host origin are easily seen. To further characterise the
blood vessels, we used fluorochrome-conjugated antibodies
specific for surface markers present on the endothelial cells.
Despite the relatively large size of these antibody molecules, they
were found to diffuse throughout the tissue. All of the antibodies
used in these experiments were of the IgG class, which is known to
be present in tissues and may have been selected over evolutionary
time to be able to penetrate many tissues and organs easily. Early
experiments established the effectiveness of the staining by
verifying that PE-anti-CD31-stained vessels and GFP
þ vessels
were colocalized. The ability to stain with antibodies greatly
expands the power of the whole mount technique in that it enables
one to use the large number of fluorochrome-conjugated reagents
that have been developed for flow cytometry. Thus, this technique
combines many of the best features of flow cytometry and
immunohistochemistry in a method that is simple to perform.
We have used this technique to determine how IL-12 alters the
angiogenic properties of tumour cells. Our results indicate that IL-
12 inhibits angiogenesis in B16 mouse tumours by downregulating
the expression of VEGFR-3. By using B16 tumour cells transfected
with the genes for IL-12, we were able to grow tumours in which
the cytokine was produced and secreted locally within the tumour
microenvironment. This ensured high local concentrations of the
cytokine while limiting side effects evident when this cytokine is
delivered systemically (Car et al, 1999). This local production of
the cytokine greatly decreased the tumorigenicity of the tumour
cells, consistent with earlier reports for B16 tumours treated
systemically (Brunda et al, 1993; Smyth et al, 2000) and engineered
to produce IL-12 locally (Nanni et al, 1998). These previous studies
(Coughlin et al, 1995, 1997, 1998; Sgadari et al, 1996) focused
mainly on the role of IL-12 in stimulating immune cells to alter
tumorigenicity, but other studies have also examined IL-12’s
effects on angiogenesis in additional tumour model systems when
the cytokine was delivered systemically. IL-12 has been shown to
regulate the level of VEGF-A in a mouse mammary tumour model
(Dias et al, 1998). However, the marked differences in the
morphology of the blood vessels in the IL-12-expressing tumours
have not been described previously, and there is no prior
information available on the mechanisms involved in the alteration
of vessel formation by these cytokines.
There is compelling evidence that angiogenesis in tumours is
initiated by the hypoxic conditions that develop as a result of
oxygen consumption by rapidly growing tumour cells (Vaupel,
1977; Pilch et al, 2001). The hypoxia stimulates the tumour cells to
increase production of various angiogenic factors, of which the
VEGF family members and their receptors play a dominant role in
many tumour models (Veikkola and Alitalo, 1999). The primary
member is VEGF-A, which is expressed by many tumour cells and
binds to VEGFR-2, thought to be the main signal transducing
receptor (Veikkola et al, 2000). Recently, two other family
members, VEGF-C and VEGF-D, have also been implicated in
tumour angiogenesis (Cao et al, 1998; Valtola et al, 1999; White
et al, 2002). These ligands, like VEGF-A, bind VEGFR-2 but in
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Figure 7 Altered expression of VEGFR-3 on blood vessels in IL-12-
expressing tumours. (A) Whole mount preparations of B16 (top row) and
B16/IL-12 (bottom row) tumours were stained with biotin-conjugated anti-
VEGFR-3 and PE–streptavidin and viewed for green fluorescence (left
images) or red fluorescence (right images). All images are of the same
magnification; the bar represents 100mm. (B) Cryrostat sections (4mm)
were prepared from B16 (top row) and B16/IL-12 (bottom row) tumours
and stained with PE-anti-CD31 and with biotin-conjugated anti-VEGFR-3
and APC–streptavidin and viewed for PE fluorescence (left images) or
APC fluorescence (right images). All images are of the same magnification;
the bar represents 100mm.
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saddition also bind VEGFR-3 (Taipale et al, 1999). We have shown
that mRNA for VEGF-A, -B, -C and -D is present within B16 and
B16/IL-12 tumours grown in vivo (data not shown). Initially, it was
thought that VEGFR-2 was expressed on both blood vascular and
lymphatic endothelial cells, whereas VEGFR-3 expression was
limited to lymphatic vessels and fenestrated endothelium (Parta-
nen et al, 2000). However, more recently it has been clearly
demonstrated that VEGFR-3 expression is upregulated on the
blood vessels within tumours of multiple types including
melanoma, colon and breast (Valtola et al, 1999; Achen et al,
2001; White et al, 2002). A recent paper has suggested that
expression of VEGFR-3 could be used as a progression marker in
human cutaneous melanoma (Clarijs et al, 2002). In the B16 mouse
model used in these studies, expression of both VEGFR-2 and -3
was detected on the blood vessels within the tumours, and
angiogenesis within the tumours was clearly evident. However, in
the tumours expressing IL-12, VEGFR-2 was present, but the
vessels failed to upregulate VEGFR-3. The vessels within these IL-
12-expressing tumours were small and less numerous, with little
evidence of any active angiogenic process. It would thus appear
that prevention of VEGFR-3 expression is an important mechan-
ism in the antiangiogenic effects of IL-12. Furthermore, this result
suggests that the ligands for VEGFR-3, VEGF-C and VEGF-D may
play an important role in the angiogenesis observed in this tumour
system. It is interesting that although these ligands, like VEGF-A,
can also bind to VEGFR-2, the downregulation of VEGFR-3 by IL-
12 still has a marked effect on the tumour vasculature despite the
unaltered expression of VEGFR-2 in the presence of IL-12. At least
for the B16-tumour system, VEGFR-3 appears to play a greater role
in tumour angiogenesis than previously appreciated.
The IL-12-mediated effects we observed in this model tumour
system appear to be mediated primarily via IFN-g. Injection of the
IL-12-transduced tumour cells into IFN-g-deficient mice resulted
in tumours that grew with kinetics similar to the parental tumours
(data not shown), and the vessel morphology was similar
(although not identical) to that of the vessels in the parental
tumour and the vessels expressed the VEGFR-3 (data not shown).
In some tumour models, the IL-12 effects have been shown to
require tumour cells that are responsive to IFN-g (Coughlin et al,
1998), implying that the tumour cells are producing additional
factors in response to IFN-g that subsequently alter the angiogenic
process. Candidate molecules for this activity include the
chemokines, IP-10 and MIP-1, although it is not completely clear
how these molecules function to suppress angiogenesis. It will be
interesting to determine whether the shared receptor for these
molecules, CXCR3, which is expressed on activated T cells is also
expressed on the vascular endothelial cells within the tumours, as
has recently been shown for human kidney tumours (Romagnani
et al, 2001). An earlier in vitro study has indicated that IL-12-
activated CD4
þ and CD8
þ T cells, as well as natural killer (NK)
cells can affect the function of endothelial cells (Strasly et al, 2001).
These cells may also play a role in regulation by IL-12 of VEGFR-3
expression on endothelial cells within tumours.
By using whole mounts of viable tumour tissue growing in
GFP
þ transgenic mice, we have been able to visualise the
vasculature within B16 tumours and observe the effects of locally
produced IL-12 on the tumour vessels. This technique combined
with immunohistochemistry has allowed us to determine that the
antiangiogenic effect of IL-12, at least in this tumour model is
related to the marked downregulation of VEGFR-3 expression on
the endothelial cells of the tumour vasculature. These results
emphasise the importance of these growth factor receptors in the
angiogenic process and suggest new possibilities for tumour
control.
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